ArticleThe oncologist2023

Comparative Effectiveness of Front-Line Ipilimumab and Nivolumab or Axitinib and Pembrolizumab in Metastatic Clear Cell Renal Cell Carcinoma.

Kevin K Zarrabi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.